Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Simcere Subsidiary, Accused Of Illicitly Producing Substandard Rabies Vaccine, Faces Fine Of RMB 25 Million In China

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - Simcere Pharmaceutical Group, maker of innovative drugs and branded generics, has announced disappointing first quarter results, hindered by ongoing difficulties at vaccine maker Jiangsu Yanshen Biological Technology and a sales decline for some traditional best sellers

You may also be interested in...



Investigators Deepen Criminal Probe Into Chinese Vaccine Producer; Regulators Revoke Production License For Rabies Inoculation

BEIJING - Executives at leading Chinese drug maker Simcere Pharmaceutical disclosed that regulators have revoked the production license for a rabies vaccine made by recently acquired Jiangsu Yanshen Biological Technology

While Cementing Partnership With U.S. Biotech Firm, Cash-rich Simcere Launches Twin Acquisitions Targeting Biosimilar, Vaccine Outfits In China

BEIJING - Fresh after cementing a new partnership with a San Francisco-based biologics firm, Simcere Pharmaceutical Group has launched twin acquisitions aimed at simultaneously expanding into the biosimilar and vaccine sectors, according to Simcere's leadership

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

OM011382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel